Veracyte
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.
C2i Genomics
Acquisition in 2024
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.
HalioDx
Acquisition in 2021
HalioDx is a company focused on designing and developing diagnostic tests in oncology that assess the immune contexture of cancers. It offers a range of immunologic scoring tests that investigate the immune response within the tumor environment. Utilizing a proprietary set of immune biomarkers and advanced image analysis technologies, HalioDx's tests accurately measure the immune reaction in and around tumors. This information helps clinicians evaluate the severity of a patient's disease and predict their response to treatment, ultimately aiding in personalized patient care.
Decipher Biosciences
Acquisition in 2021
Decipher Biosciences, Inc. is a genomic information company focused on developing and commercializing clinical tests for urologic cancers. The company offers the Decipher Prostate Biopsy test, which analyzes tumor tissue to help determine appropriate treatment based on the tumor's metastatic potential. Additionally, it provides the Decipher Bladder test, a genomic subtyping tool that classifies muscle-invasive bladder cancer and identifies patients who may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences has a research and development center in Vancouver, Canada. The company is also building the GRID database, which contains over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to discover biomarkers that indicate responses to new therapies.
Allegro Diagnostics
Acquisition in 2014
Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The company specializes in the development and commercialization of genomic tests aimed at diagnosing, staging, and guiding the treatment of lung cancer and other lung diseases. Allegro's molecular testing platform employs a genomic biomarker to assess changes in gene expression in the airway's epithelial cells, allowing for the early detection of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare providers with essential diagnostic information, facilitating quicker diagnosis and treatment decisions for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.